中华医学杂志（英文版）2020，Vol.133Issue(9)：1099-1108,10.DOI:10.1097/CM9.0000000000000745
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Le-Sang Shen 1Xiao-Yan Jin 2Xu-Meng Wang 3Lai-Zhen Tou 4Jian Huang4
作者信息
- 1. Department of Breast Surgery, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China
- 2. Key Laboratory of Tumor Microenvironment and Immune Therapy of Zhejiang Province, Hangzhou, Zhejiang 310009, China
- 3. Department of Surgical Oncology, Zhejiang Taizhou Municipal Hospital, Taizhou, Zhejiang 318000, China
- 4. Department of Surgical Oncology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China
- 折叠
摘要
关键词
Endocrine therapy/Advanced breast cancer/Endocrine resistance/Targeted therapyKey words
Endocrine therapy/Advanced breast cancer/Endocrine resistance/Targeted therapy引用本文复制引用
Le-Sang Shen,Xiao-Yan Jin,Xu-Meng Wang,Lai-Zhen Tou,Jian Huang..Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer[J].中华医学杂志（英文版）,2020,133(9):1099-1108,10.
